Green shoots in Hong Kong as Jiangsu Hengrui, Mirxes list on HKSE

At a time when the NASDAQ biotech IPO window is all but closed, the Hong Kong exchange is suddenly stirring, with a pair of listings this week and another poised to price Monday.

Jiangsu Hengrui Pharmaceutical Co. Ltd. (Shanghai:600276; HKEX:1276) priced its Hong Kong listing this week to raise HK$9.9 billion (US$1.3 billion). The former generics play turned global innovator is part of a wave of established mainland companies seeking secondary listings on the Hong Kong stock exchange...